Analysis of eosinophil cationic protein in nasal secretion for monitoring of sequential therapy in seasonal allergic rhinitis;ECP-kontrollierte sequenztherapie bei allergischer rhinitis

H+G Zeitschrift fur Hautkrankheiten

Volumn 72, Issue 6, 1997, Pages 441-446

  Mosges R ^a   Klimek, L ^b   Spaeth, J ^c   Reineke, Th ^c   Brand, C ^d   Gode U ^d   Hauswald, B ^d   Kupper J ^d   Modi, R ^d   Muhlbauer J ^d   Palm, J ^d   Panzer, B ^d   Peters, F ^d   Riedelsheimer, B ^d   Schindelbeck, G ^d   Schlee, J ^d   Sondermann, M ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d NONE

Author keywords

Allergic rhinitis; Antihistamines; Azelastine; Eosinophil cationic protein

Indexed keywords

AZELASTINE;

ALLERGIC RHINITIS; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG FORMULATION; EOSINOPHIL; HUMAN; INTRANASAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; RANDOMIZED CONTROLLED TRIAL; SEASONAL VARIATION; TOPICAL DRUG ADMINISTRATION; TREATMENT PLANNING;

EID: 8544226290     PISSN: 03010481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Albegger K. Symptomatische Therapie der allergischen Rhinitis. Laryngo-Rhino-Otol. 69, 613 -620 (1990)
2. Andersson M, Andersson P, Venge P, Pipkorn U. Eosinophils and eosinophil cationic protein in nasal lavages in allergen-induced hyperresponsiveness' effects of topical glucocorticosteroid treatment. Allergy 1989; 44: 342 - 348
3. Ayars GH, Altman LC, McManus MM. Agosti JM, Baker C, Luchtel DL, Loegering DA, Gleich GJ. Injurious effect of the eosinophil peroxidehydrogen peroxide-halide system and major basic protein on human nasal epithelium in vitro. Am Rev Respir Dis 1989; 140:125 - 131
4. Bachert C., C. Colberg. Gegenwartiger Stand der symptomatischen Therapie bei der allergischen Rhinitis. HNO 38, 1 - 6 (1990)
5. Bahre M, Klimek L, Mölich J, Mösges R. Azelastine reduces release of Eosinophil Cationic Protein (ECP). Allergy 26: 50 (1995) 102
6. Capron M. Eosinophils: Receptors and mediators in hypersensitivity. Clin Exp Allergy 1989; 19 (Suppl.1):3 - 8
7. Davies BH, Mullins J. Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis. Allergy 1993; 48: 519 - 524
8. Davies R. J., S. Olliver, D. R. Cundell. Drug treatment for nasal allergy. Clin Exp Allergy 1989; 19: 559 - 68
9. Dorow P, Aurich R, Petzold U. Efficacy and tolerability of azelastine nasal spray in patients with allergic rhinitis compared to placebo and budesonide. Arzneimforsch/Drug Res 1993; 43: 909-12
10. Gastpar H, Dorow P, Aurich R, Petzold U. Investigation of long-term efficacy and tolerabilrty of azelastine nasal spray in the treatment of perennial allergic rhinitis. Arzneim Forschung/ Drug Research 1993; 43: 771 - 76
11. Grossman J, Halverson PC. Meltzer EO, Shoenwetter WF, vanBavel JH, Woehler TR, Freitag JF, Hemsworth GR. Double-blind assessment of azelastine in the treatment of perennial allergic rhinitis. Ann Allergy 1994; 73: 141-46
12. Johansson SGO, Deuschl H. Immunogiobulins in nasal secretions with special reference to IGE. L Methodological Studies. Int Arch Allergy Appl Immunoi 1976; 52: 364 - 375
13. Kapp A. Atopische Dermatitis - die Hautmanifestation der Atopie Allergo Journal 1995; 4: 229 -38
14. Klimek L, Riechelmann H, Burow G. Eosinophil Cationic Protein in nasal secretions and blood plasma in patients allergic to grass-pollen. Abstract Book of the 15th European Rhinologic Congress Kopenhagen, 1994; 388 - 389
15. Leiferman KM. A current perspective on the role of eosinophils in dermatologic diseases. J Am Acad Dermatol 1991; 24: 1101 - 12
16. Livostin Study Group. A comparison of topical levocabastine and oral terfenadine in the treatment of allergic rhinoconjunctivitis. Allergy 1993; 48: 530-34
17. Molich J, Klimek L, Bähre M, Mosges R. Combined topical and systemic treatment with azeiastine nasal spray and tablets in severe cases of allergic rhino-conjunctivitis. Allergy 26: 50 (1995) 102
18. Mosges R, Klimek L, Spaeth J, Schultze V Topische versus systemische Antihisiaminikatherapie der saisonalen Rhinitis allergica. Wirksamkeit und Verträglichkeit von Azelastin-Nasenspray im Vergleich mit Cetirizin-Tabletten, Allergologie, 18 (1995) 145 -150
19. Peterson CGB, Enander I, Nystrand J, Anderson AS, Nilsson L, Venge P. Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels and turnover in vivo. Clin Exp Allergy 1991; 21:561 -7
20. Rasp G, Thomas BA, Bujia J. Eosinophil inflammation of the nasal mucosa in allergic and non-allergic rhinitis measured by eosinophil cationic protein levels in native nasal fluid and serum. 1994; Clin Exp Allergy 24: 1151 - 1156
21. Simons FER. The antiallergic effects of antihistamines (H1-receptor antagonists). J Allergy Clin Immunol 1992; 90: 705 - 15
22. Spaeth J, Mösges R, Klimek L. Nicht-sedieren-de Antihistaminika : Wunsch oder Wirklichkeit ? Allergofogie 17, 5 (1994) 204 - 207
23. Thomas KE, Ollier S, Ferguson H, Davies RJ. The effect of intranasal azelastine, Rhinolast, on nasal airway obstruction and sneezing following provocation testing with histamine and allergen. Clin Exp Allergy 1992; 22: 642 - 47
24. Venge P. Soluble markers of allergic inflammation. Allergy 1994; 49: 1 - 8
25. Wailer JM, Donnelly A, Campbell BH, Connell JT, Diamond L, Hamilton LH, Rosenthal RR, Hemsworth GR, Perhach JL Multicentre, double-blind, multiple dose, parallel groups efficacy and safety trial of azelastine, chlorpheniramine and placebo in the treatment of spring allergic rhinitis. J Allergy Clin Immunol 1988; 82: 801 -811